Format

Send to

Choose Destination
Hormones (Athens). 2018 Dec;17(4):573-579. doi: 10.1007/s42000-018-0083-8. Epub 2018 Nov 22.

Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.

Author information

1
First Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. spolyzos@auth.gr.
2
Second Medical Clinic, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
3
Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
4
Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece.
5
FIANOSTICS GmbH, Wiener Neustadt, Austria.
6
Department of Internal Medicine, University Hospital Inselspital, Bern, Switzerland.
7
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Abstract

AIM:

The evaluation of (a) noggin levels in patients with simple steatosis (SS) vs. nonalcoholic steatohepatitis (NASH) vs. controls, and (b) the effect of combined spironolactone plus vitamin E vs. vitamin E monotherapy on noggin levels in biopsy-proven patients with nonalcoholic fatty liver disease (NAFLD).

METHODS:

In the case-control study, 15 patients with SS, 16 with NASH, and 24 controls were included. In the randomized controlled trial, NAFLD patients were assigned to vitamin E (400 IU/d) or spironolactone (25 mg/d) plus vitamin E for 52 weeks.

RESULTS:

Noggin levels were lower in SS (5.8 ± 1.5 pmol/l) and NASH (8.7 ± 2.4 pmol/l) patients than in controls (13.7 ± 2.7 pmol/l; p for trend = 0.040), but were similar in SS and NASH patients. After adjustment for potential cofounders, log(noggin) remained different between groups. Log(noggin) levels similarly increased post-treatment in both groups: log(noggin) was not different between groups (p = 0.20), but increased within groups over time (p < 0.001), without a significant group × time interaction (p = 0.62). Log(noggin) significantly increased at month 2 post-treatment (p = 0.008 vs. baseline) and remained stable thereafter.

CONCLUSIONS:

Lower noggin levels were observed in NAFLD patients than in controls. Noggin levels increased similarly by either combined low-dose spironolactone plus vitamin E or vitamin E monotherapy.

TRIAL REGISTRATION:

NCT01147523.

KEYWORDS:

Bone morphogenetic protein; Noggin; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Oxidative stress; Simple steatosis

PMID:
30467685
DOI:
10.1007/s42000-018-0083-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center